$CMPX
Compass Therapeutics, Inc.

2022 Q1 Form 10-K Financial Statement

#000095017022004156 Filed on March 18, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.767M $3.427M $10.93M
YoY Change 5.01% -3.3% -15.35%
% of Gross Profit
Research & Development $4.415M $9.574M $20.34M
YoY Change -6.14% 117.1% 36.45%
% of Gross Profit
Depreciation & Amortization $200.0K $124.0K $600.0K
YoY Change 0.0% -88.4% -75.0%
% of Gross Profit
Operating Expenses $7.182M $13.00M $81.88M
YoY Change -2.14% 63.53% 194.41%
Operating Profit -$7.182M -$81.88M
YoY Change -2.14% 194.41%
Interest Expense $0.00 -$35.00K $370.0K
YoY Change -100.0% -78.13% -59.25%
% of Operating Profit
Other Income/Expense, Net $20.00K -$299.0K
YoY Change -124.1% -81.94%
Pretax Income -$7.162M -$12.99M -$82.18M
YoY Change -3.5% 54.86% 178.88%
Income Tax $0.00 -$13.00K $0.00
% Of Pretax Income
Net Earnings -$7.162M -$12.98M -$82.18M
YoY Change -3.5% 54.7% 178.58%
Net Earnings / Revenue
Basic Earnings Per Share -$0.07 -$1.31
Diluted Earnings Per Share -$71.01K -$150.1K -$1.307M
COMMON SHARES
Basic Shares Outstanding 101.3M 98.03M 62.87M
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $136.4M $144.5M $144.5M
YoY Change 243.57% 206.98% 206.98%
Cash & Equivalents $136.4M $144.5M $144.5M
Short-Term Investments $0.00
Other Short-Term Assets $3.904M $2.591M $2.591M
YoY Change 100.0% -17.11% -17.11%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $140.3M $147.1M $147.1M
YoY Change 236.84% 193.03% 193.03%
LONG-TERM ASSETS
Property, Plant & Equipment $2.142M $2.243M $6.332M
YoY Change -64.77% 99.2% 462.34%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $320.0K $320.0K $320.0K
YoY Change -32.06% 0.0% -45.11%
Total Long-Term Assets $6.281M $6.652M $6.652M
YoY Change -4.12% 289.23% 289.23%
TOTAL ASSETS
Total Short-Term Assets $140.3M $147.1M $147.1M
Total Long-Term Assets $6.281M $6.652M $6.652M
Total Assets $146.6M $153.8M $153.8M
YoY Change 204.09% 196.19% 196.19%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $257.0K $867.0K $867.0K
YoY Change -75.78% -18.28% -18.28%
Accrued Expenses $8.050M $8.775M $9.764M
YoY Change 524.03% 458.56% 521.51%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0% -100.0%
Total Short-Term Liabilities $9.334M $10.63M $10.63M
YoY Change -13.97% 5.27% 5.27%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $2.740M $3.048M $3.048M
YoY Change -29.33%
Total Long-Term Liabilities $2.740M $0.00 $3.048M
YoY Change -29.33% -100.0% 63.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.334M $10.63M $10.63M
Total Long-Term Liabilities $2.740M $0.00 $3.048M
Total Liabilities $12.07M $13.68M $13.68M
YoY Change -18.01% 14.32% 14.32%
SHAREHOLDERS EQUITY
Retained Earnings -$240.8M -$233.6M
YoY Change 54.28%
Common Stock $375.2M $373.7M
YoY Change 95.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $134.5M $140.1M $140.1M
YoY Change
Total Liabilities & Shareholders Equity $146.6M $153.8M $153.8M
YoY Change 204.09% 196.19% 196.19%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$7.162M -$12.98M -$82.18M
YoY Change -3.5% 54.7% 178.58%
Depreciation, Depletion And Amortization $200.0K $124.0K $600.0K
YoY Change 0.0% -88.4% -75.0%
Cash From Operating Activities -$7.942M -$4.665M -$19.67M
YoY Change 41.69% -29.03% -26.63%
INVESTING ACTIVITIES
Capital Expenditures $194.0K -$777.0K $1.568M
YoY Change 51.56% 836.14% 1379.25%
Acquisitions $318.0K
YoY Change
Other Investing Activities $1.000K $1.000K $116.0K
YoY Change -99.13% -98.88% -19.44%
Cash From Investing Activities -$193.0K -$776.0K -$1.770M
YoY Change 1384.62% -13033.33% -4757.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $128.3M
YoY Change 112.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 124.2M 118.6M
YoY Change -100.0% -6725.92% 144.37%
NET CHANGE
Cash From Operating Activities -7.942M -4.665M -19.67M
Cash From Investing Activities -193.0K -776.0K -1.770M
Cash From Financing Activities 0.000 124.2M 118.6M
Net Change In Cash -8.135M 118.8M 97.18M
YoY Change 8.57% -1507.19% 346.31%
FREE CASH FLOW
Cash From Operating Activities -$7.942M -$4.665M -$19.67M
Capital Expenditures $194.0K -$777.0K $1.568M
Free Cash Flow -$8.136M -$3.888M -$21.23M
YoY Change 41.92% -40.09% -21.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001738021
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
000-55939
CY2021 dei Entity Registrant Name
EntityRegistrantName
Compass Therapeutics, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-4876496
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
80 Guest Street
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 601
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02135
CY2021 dei City Area Code
CityAreaCode
617
CY2021 dei Local Phone Number
LocalPhoneNumber
500-8099
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
CMPX
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
Yes
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q2 dei Entity Public Float
EntityPublicFloat
180000000
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
101302594
CY2020Q4 us-gaap Assets
Assets
51911000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
867000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Assets
Assets
153757000
CY2021 dei Auditor Firm
AuditorFirmId
596
CY2021 dei Auditor Name
AuditorName
CohnReznick LLP
CY2021 dei Auditor Location
AuditorLocation
Melville, NY U.S.A
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
144514000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47076000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2591000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3126000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
147105000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
50202000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2243000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1126000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
0
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
263000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4089000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1061000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8775000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1571000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
989000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
0
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7467000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10631000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
10099000
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1867000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3048000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2021Q4 us-gaap Liabilities
Liabilities
13679000
CY2020Q4 us-gaap Liabilities
Liabilities
11966000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
101303000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52117000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-299000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1656000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-82181000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-29468000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100832000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
51221000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
10000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
373657000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
191348000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-233589000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-151408000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
140078000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
39945000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
153757000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51911000
CY2021 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
20337000
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
14904000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10927000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12908000
CY2021 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
50618000
CY2020 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
0
CY2021 us-gaap Operating Expenses
OperatingExpenses
81882000
CY2020 us-gaap Operating Expenses
OperatingExpenses
27812000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-81882000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-27812000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-82181000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-29500000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.31
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.96
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62870000
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30776000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11267000
CY2020 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6300000
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
54231000
CY2020 cmpx Payment To Non Participating Members Upon Consummation Of Merger
PaymentToNonParticipatingMembersUponConsummationOfMerger
69000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4016000
CY2020 cmpx Net Loss
NetLoss
-29500000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
39945000
CY2021 us-gaap Stock Issued During Period Shares Acquisitions
StockIssuedDuringPeriodSharesAcquisitions
10265000
CY2021 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
50300000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
8500000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
127985000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4029000
CY2021 cmpx Net Loss
NetLoss
-82181000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
140078000
CY2021 us-gaap Profit Loss
ProfitLoss
-82181000
CY2020 us-gaap Profit Loss
ProfitLoss
-29500000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
566000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2404000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
42000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-281000
CY2021 cmpx Non Cash Interest Expense
NonCashInterestExpense
41000
CY2020 cmpx Non Cash Interest Expense
NonCashInterestExpense
90000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4029000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4016000
CY2021 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
50618000
CY2020 us-gaap Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
0
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-556000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1058000
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-534000
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2191000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2020 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
290000
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-194000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
432000
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7016000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1551000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1111000
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
CY2021 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
0
CY2020 us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-1050000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19666000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-26803000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1568000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
106000
CY2021 cmpx Payments For Asset Acquisition Costs
PaymentsForAssetAcquisitionCosts
318000
CY2020 cmpx Payments For Asset Acquisition Costs
PaymentsForAssetAcquisitionCosts
0
CY2021 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
116000
CY2020 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
144000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1770000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
38000
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
128267000
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
60482000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
281000
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
6319000
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
9375000
CY2020 us-gaap Repayments Of Debt
RepaymentsOfDebt
5625000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
118611000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
48538000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
97175000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
21773000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47339000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
25566000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
144514000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
47339000
CY2021 us-gaap Interest Paid Net
InterestPaidNet
370000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
854000
CY2021 cmpx Noncash Or Part Noncash Conversion Of Preferred Units
NoncashOrPartNoncashConversionOfPreferredUnits
0
CY2020 cmpx Noncash Or Part Noncash Conversion Of Preferred Units
NoncashOrPartNoncashConversionOfPreferredUnits
129870000
CY2021 cmpx Noncash Or Part Noncash Right Of Use Asset Acquired Through Operating Leases
NoncashOrPartNoncashRightOfUseAssetAcquiredThroughOperatingLeases
5148000
CY2020 cmpx Noncash Or Part Noncash Right Of Use Asset Acquired Through Operating Leases
NoncashOrPartNoncashRightOfUseAssetAcquiredThroughOperatingLeases
0
CY2021 cmpx Noncash Or Part Noncash Acquisition Of Business
NoncashOrPartNoncashAcquisitionOfBusiness
50300000
CY2020 cmpx Noncash Or Part Noncash Acquisition Of Business
NoncashOrPartNoncashAcquisitionOfBusiness
0
CY2021 cmpx Fixed Asset Costs Included In Accrued Expenses
FixedAssetCostsIncludedInAccruedExpenses
187000
CY2020 cmpx Fixed Asset Costs Included In Accrued Expenses
FixedAssetCostsIncludedInAccruedExpenses
0
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-233600000
CY2021 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
Upon the closing of the Merger, the common and convertible preferred units of Compass Therapeutics LLC were converted into the Company’s common stock. The Company effected a 0.15-for-one stock conversion ratio for its issued and outstanding convertible preferred units. Common units were converted using the same ratio after factoring in the relevant strike price of each grant.
CY2021Q4 us-gaap Common Unit Outstanding
CommonUnitOutstanding
0
CY2021Q4 us-gaap Preferred Units Outstanding
PreferredUnitsOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3055000
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:5.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Use of Estimates</span></p><p style="margin-left:5.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, the accrual of research and development expenses, useful lives of equipment, interest rate and term operating lease ROU and liability, the percentage of completion of contractual arrangements, future cash expenditures for liquidity estimates, the valuation of common stock and estimates associated with stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Actual results could differ from those estimates. Changes in estimates are recorded prospectively in the period that they become known.</span></p>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
0
CY2020Q4 us-gaap Restricted Cash
RestrictedCash
200000
CY2020Q4 us-gaap Line Of Credit
LineOfCredit
100000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:5.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Arial;">Concentrations of Credit Risk</span></p><p style="margin-left:5.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains its cash, cash equivalents and restricted cash with financial institutions that management believes to be of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span></p><p style="margin-left:5.333%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">high-credit quality.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Arial;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;">The Company has not experienced any losses related to its cash, cash equivalents and restricted cash.</span></p>
CY2021 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2021Q4 cmpx Dividend Yield
DividendYield
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5330000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7269000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
7061000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5026000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5935000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2243000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1126000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
600000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2400000
CY2021Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1601000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
976000
CY2021Q4 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
704000
CY2020Q4 cmpx Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
212000
CY2021Q4 cmpx Accrued Milestone Current
AccruedMilestoneCurrent
6000000
CY2020Q4 cmpx Accrued Milestone Current
AccruedMilestoneCurrent
0
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
470000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
383000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8775000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1571000
CY2021 cmpx Payment To Several Nonaccredited Investors
PaymentToSeveralNonaccreditedInvestors
100000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4029000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4016000
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4210000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.01
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7100000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
12300000
CY2021 cmpx Number Of Operating Lease
NumberOfOperatingLease
1
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y5M
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0625
CY2021Q4 us-gaap Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
P3Y5M
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1206000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1348000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1382000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
426000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4362000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
325000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
4037000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
989000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3048000
CY2021 us-gaap Interest Expense
InterestExpense
370000
CY2020 us-gaap Interest Expense
InterestExpense
908000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
29000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
88000
CY2021 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
0
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-556000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
0
CY2020 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1000
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
42000
CY2020 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-281000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-299000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1656000
CY2020 cmpx Research And Development Credits Carryforwards
ResearchAndDevelopmentCreditsCarryforwards
2100000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
13075000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
100
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
200
CY2021 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
22000
CY2021 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
10000
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0
CY2020 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
32000
CY2021 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
-0.000
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Exempt Income
EffectiveIncomeTaxRateReconciliationTaxExemptIncome
-0.080
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.021
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.064
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.010
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.005
CY2021 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
-0.129
CY2020 us-gaap Effective Income Tax Rate Reconciliation Deductions Other
EffectiveIncomeTaxRateReconciliationDeductionsOther
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.008
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.000
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.100
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.190
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18100000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6600000
CY2021 cmpx Research And Development Credits Carryforwards
ResearchAndDevelopmentCreditsCarryforwards
1100000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
3938000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2716000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2038000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
706000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
609000
CY2021Q4 cmpx Lease Liabilities
LeaseLiabilities
1131000
CY2020Q4 cmpx Lease Liabilities
LeaseLiabilities
0
CY2021Q4 cmpx Capitalized Licensing Fees
CapitalizedLicensingFees
1637000
CY2020Q4 cmpx Capitalized Licensing Fees
CapitalizedLicensingFees
0
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
22000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
126000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19287000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
6711000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18113000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
6635000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1174000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
76000
CY2021Q4 cmpx Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
-1116000
CY2020Q4 cmpx Deferred Tax Liabilities Right Of Use Assets
DeferredTaxLiabilitiesRightOfUseAssets
0
CY2021Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
-58000
CY2020Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
-76000
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0

Files In Submission

Name View Source Status
0000950170-22-004156-index-headers.html Edgar Link pending
0000950170-22-004156-index.html Edgar Link pending
0000950170-22-004156.txt Edgar Link pending
0000950170-22-004156-xbrl.zip Edgar Link pending
cmpx-20211231.htm Edgar Link pending
cmpx-20211231.xsd Edgar Link pending
cmpx-20211231_cal.xml Edgar Link unprocessable
cmpx-20211231_def.xml Edgar Link unprocessable
cmpx-20211231_htm.xml Edgar Link completed
cmpx-20211231_lab.xml Edgar Link unprocessable
cmpx-20211231_pre.xml Edgar Link unprocessable
cmpx-ex23_1.htm Edgar Link pending
cmpx-ex31_1.htm Edgar Link pending
cmpx-ex31_2.htm Edgar Link pending
cmpx-ex32_1.htm Edgar Link pending
cmpx-ex32_2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img118710839_0.jpg Edgar Link pending
img118710839_1.jpg Edgar Link pending
img118710839_10.jpg Edgar Link pending
img118710839_11.jpg Edgar Link pending
img118710839_12.jpg Edgar Link pending
img118710839_13.jpg Edgar Link pending
img118710839_14.jpg Edgar Link pending
img118710839_15.jpg Edgar Link pending
img118710839_16.jpg Edgar Link pending
img118710839_17.jpg Edgar Link pending
img118710839_2.jpg Edgar Link pending
img118710839_3.jpg Edgar Link pending
img118710839_4.jpg Edgar Link pending
img118710839_5.jpg Edgar Link pending
img118710839_6.jpg Edgar Link pending
img118710839_7.jpg Edgar Link pending
img118710839_8.jpg Edgar Link pending
img118710839_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending